Constellation Pharmaceuticals jumped on Wednesday after a favorable preliminary Phase 2 clinical trial for a drug treatment for patients with Myelofibrosis.
All four patients achieved at least a 35% reduction in spleen volume and at least a 50% improvement in total symptom score as early as three months after treatment, the study showed.
The drug, called MANIFEST, is expected to end its primary testing period in August 2021.
Shares of Constellation Pharmaceuticals (NASDAQ:CNST) surged nearly 112% in midday trade.
